T h e ne w e ngl a nd jou r na l o f m e dic i ne 
The Clinic a l Problem
Colorectal cancer is the second leading cause of death from cancer in the United States. This year, it is estimated that there will be 147,000 newly diagnosed cases of colo rectal cancer and nearly 50,000 deaths associated with this disease. 1 The ageadjusted incidence of colorectal cancer in the United States is 61.2 cases per 100,000 popula tion among men and 44.8 per 100,000 population among women. 1 These rates have been slowly decreasing since 1985.
There is considerable evidence that screening of asymptomatic persons who are at average risk can detect cancers at an early and curable stage, resulting in a reduc tion in mortality. [2] [3] [4] Furthermore, some screening tests may also detect cancerpre cursor lesions, which, if removed, may result in a reduced incidence of colorectal cancer. 5 There are several different screening tests, each with advantages and limita tions (Table 1) ; differences among strategies in terms of the sensitivity and speci ficity of the tests, their complexity, and the associated risk complicate the process of informed decision making.
S tr ategies a nd Ev idence

Identification of High-Risk Persons
The most common indicator of high risk is a firstdegree relative with colorectal cancer. If the firstdegree relative had colorectal cancer before 50 years of age, there should be suspicion of hereditary syndromes such as familial adenomatous polyposis, hereditary nonpolyposis colorectal cancer syndrome, and MutY homolog (MUTYH) polyposis. Such patients require special screening and should be referred to a special ist with expertise in these hereditary syndromes to obtain a complete family history, consider genetic counseling and testing, and determine appropriate timing for endo scopic surveillance. If a firstdegree relative had colorectal cancer at 50 years of age or older, the lifetime risk of colorectal cancer nearly doubles among his or her family members. Colonoscopy is the preferred screening test in these persons, and screening should be initiated either when they are 40 years old or when they are 10 years younger than the age at which the family member received a diagnosis of colorectal cancer, whichever comes first. 9 Patients with chronic ulcerative colitis or colitis due to Crohn's disease are at increased risk for colorectal cancer and should undergo surveillance with colonoscopy, generally beginning 8 to 10 years after diagnosis.
Prevention Strategies for Average-Risk Persons
Factors associated with an increased risk of colo rectal cancer include dietary factors (diets high in fat or low in fiber, calcium, or both), obesity, low levels of physical activity, tobacco smoking, and a high alcohol intake. Although lifestyle choices may contribute to the risk of colorectal cancer, there is little evidence that a modification of lifestyle in adults will reduce this risk. 10 The regular use of aspirin or nonsteroidal antiinflammatory drugs and the use of hormonereplacement therapy have reduced the risk of new adenomas or cancer. 11, 12 However, these agents have potential adverse ef fects that may offset any potential benefit with re spect to the prevention of colorectal cancer and are not recommended for this indication. 3
Screening Tests and Strategies
Fecal Screening Tests
Fecal screening tests can detect occult blood in small stool samples. These tests can be performed at home, are noninvasive, have a low initial cost, and require few specialized resources. There are Clinical trials have shown that persons with positive occultblood tests have a risk of cancer that is three to four times as high as that among persons with negative tests, and colonoscopy should be recommended for persons with these positive tests. Randomized, controlled trials in which standard guaiac tests were administered annually or biennially have shown that cancers are detected at an early and more curable stage in persons who undergo screening than in persons who are not screened; over a period of 10 to 13 years, this results in a reduction in mortality from colorectal cancer of 15 to 33%. [13] [14] [15] Fecal occultblood testing has important lim itations. Because of the relatively poor sensitivity of onetime standard testing ( (Table 2) .
Surveys reveal that many health care providers consider a fecal test performed during an office digital examination to be "opportunistic" screen ing and "better than nothing." 30 Such tests have low sensitivity for the detection of highrisk ad enomas and cancer, 32 may provide false reassur ance to patients, and are not recommended for screening. 2 Although the initial cost of fecal occultblood testing is low, an appropriate analysis of costs should include the costs of annual testing, re minder systems, colonoscopy in patients with positive tests, and treatment for detected cancers. When all these factors are considered, the costs of screening by means of fecal occultblood tests are similar to those of screening by means of flex ible sigmoidoscopy or colonoscopy. 33 Another fecal test can detect abnormal DNA in stool samples. Stool DNA tests are based on the research findings that specific mutations are as sociated with colorectal cancer and that cellular DNA is excreted in stool and can be detected with the use of polymerasechainreaction methods. In a study involving an early version of this test in asymptomatic patients undergoing colonoscopy, 51% of cancers and 18% of advanced cancerpre cursor lesions were detected by means of the test. 16 New versions of the test appear to have greater sensitivity 17,19 but have not yet been carefully evalu ated in screening cohorts. Thus, the overall test performance remains uncertain, as does the ap propriate treatment of patients with positive tests and negative colonoscopic findings, the appropri ate screening interval, and the costeffectiveness of this test.
Structural Examinations of the Colon
Structural examinations of the colon have been shown to be effective for the detection of both can cerprecursor lesions and early cancer (Table 2) . These tests may prevent the development of can cer through the detection and removal of ade nomas. 5
Radiographic Studies
Barium enema examination accurately identifies latestage cancer, but it is a poor test for impor tant cancerprecursor lesions 34 and is rarely used for colorectalcancer screening today. Imaging with computed tomographic (CT) colonography ( Fig. 1 ) renders twodimensional and threedimensional images of the colon and requires complete bowel preparation. [26] [27] [28] In clinical studies involving ex pert radiologists, 90% of polyps 10 mm or larger in diameter were identified correctly, with a false positive rate of 14%. 20 The detection rate for pol yps that are 6 mm or larger in diameter (the thresh old for referring a patient for colonoscopy) is 78% (specificity, 88%). 2 With the use of this cutoff point, 15 to 25% of persons undergoing screening would be referred for colonoscopy. 27, 28, 35 The rate of re ferral for colonoscopy is an important element of program cost.
CT colonography is less sensitive and specific for polyps smaller than 6 mm in diameter than it is for larger polyps. However, the treatment plan for a patient in whom the largest polyp is smaller than 6 mm in diameter is controversial. Less than 2% of these patients will have adenomas with ad vanced features, and cancer is rare. 35, 36 No stud ies have demonstrated the safety of following such patients with repeat CT colonography. There is also uncertainty about whether CT colonography can be used to identify flat polyps, some of which may harbor malignant cells. 37 Appropriate screen ing intervals after negative examinations or in cases of growths that are smaller than 6 mm in diameter and that may be polyps are uncertain. In addition, the sensitivity and specificity of CT colonography in routine clinical practice settings are unknown.
Several other areas of uncertainty are listed in Table 1 . Radiation exposure associated with CT colonography could increase the risk of cancer. 38 Although lowdose regimens are used, there is concern about cumulative radiation exposure, and some countries will not allow imaging for screen ing purposes. The rate of extracolonic findings that require further evaluation is an important driver of cost. Studies show that 27 to 69% of per sons who undergo screening with CT colonogra phy have at least one finding outside the colon, requiring further evaluation in 5 to 16% of persons undergoing screening. 2, 4 Sigmoidoscopy Case-control studies have shown significant as sociations between the use of sigmoidoscopy and reduced mortality from colorectal cancer in that Rockey et al.
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portion of the colon which is examined. 21 In a large, randomized, controlled trial, there was no reduction in the incidence of colorectal cancer among subjects assigned to screening sigmoi doscopy, and in an intentiontotreat analysis, there was a nonsignificant reduction in mortality at 6 years among these subjects as compared with controls. 39 However, studies with the use of screening colonoscopy have shown that more than 30% of patients with advanced neoplasia have only proximal lesions that would not be identified with sigmoidoscopy 22,23 ; this scenario is more common in women than in men and in patients older than 60 years of age than in younger patients. 22, 24, 25 The examination requires bowel preparation and an office visit and is usually associated with some discomfort. For many clinicians and patients, colonoscopy is more appealing than sigmoidos copy because patients can be sedated and undergo a complete colon examination with polypectomy. Reimbursement for sigmoidoscopy is low, relative to the resources used. All these limitations have discouraged its use in the United States.
Colonoscopy
Colonoscopy is the final assessment step in every screening program for the detection of colorectal cancer. Several large cohort studies have shown the feasibility and safety of colonoscopy as a pri mary screening test. [22] [23] [24] 40 These studies show that among patients at average risk who undergo screening colonoscopy, 0.5 to 1.0% have colon cancer and 5 to 10% have advanced neoplasia that can be removed. [22] [23] [24] [25] 40 In case-control stud ies, colonoscopy is associated with reductions in the incidence of and mortality from colorectal cancer. [6] [7] [8] No randomized, controlled trials have com pared the outcomes of colonoscopy with those of other forms of screening. Several studies have shown that among patients with an adenoma that is detected and removed at screening colonosco py, colorectal cancer may develop in 0.3 to 0.9% within 3 to 5 years after screening. Missed lesions account for some of the cancers detected at sub sequent colonoscopy. Lesions that are 10 mm or larger in diameter may be missed in 2 to 12% of patients. [26] [27] [28] The detection of flat adenomas may be especially difficult and may require special techniques. 37 Colonoscopy may not reduce the risk of proximal colon cancer unless the exami nation is complete and all polyps are removed. 8 These issues underscore the importance of mon itoring and improving the quality of colonoscopy; tools for measuring quality are now available. 41 The recommended 10year interval for repeat ex A r e a s of Uncerta int y
Uncertainties associated with individual tests are summarized in Table 1 . Screening recommenda tions do not currently vary according to age and race or ethnic group, but screening outcomes dif fer according to these characteristics. Ageadjusted rates of colorectal cancer 1 and advanced polyps 24,25 are lower among women than among men. The incidence of and mortality from colorectal cancer are higher among blacks than among whites. 1 Among persons who undergo screening with colo noscopy, rates of large polyps are higher among blacks, both men and women, than among whites. 54 Therefore, it may make sense for white women to delay screening and for black men and women to undergo the first screening before 50 years of age. The American College of Gastroenterology sup ports the initiation of screening in blacks at 45 years of age. 55 However, there are concerns that screening recommendations are already complex and that customization could paradoxically re duce screening rates. 2 There are no data from randomized trials showing that a reduction in mortality from col orectal cancer is associated with the performance of colonoscopy or CT colonography. Large trials involving sigmoidoscopy are being conducted in the United States, the United Kingdom, and Italy.
The performance and quality of screening pro grams to detect colorectal cancer in diverse clini cal practice settings remain uncertain. Further study is needed to determine rates of adherence to recommended testing and of appropriate fol lowup after initial testing, with attention to the effects of race or ethnic group and sex, to better inform patient and physician education regarding screening. Canada. Alternatives to fecal occultblood testing are sigmoidoscopy in the United Kingdom, Italy, and Norway and colonoscopy in Germany, Aus tria, Poland, and Italy.
Guidelines
Conclusions a nd R ecommendations
Colorectalcancer screening should begin with a process of informed decision making (Table 4) . Patients should be informed that there is strong evidence that screening persons who are at aver age risk is effective in reducing the risk of death from colorectal cancer, but that there is no per fect screening test and each program has advan tages, limitations, and uncertainties (Table 1) . Patients also should be informed about the "downstream" benefits and risks associated with the various screening tests, including the need for followup tests and the likelihood that the test will detect important pathologic findings, if present. Although the USPSTF does not recommend routine screening in persons older than 75 years of age, the healthy 76yearold woman in the vignette has never undergone proper screening and she should be offered it. Given that her sex and age are associated with an increased risk of neo plasia in the proximal colon, I would recommend colonoscopy. She should be referred to an endos copist who monitors quality and meets bench marks for colonoscopic examination. If this test is negative, she will not need any further screen ing in her lifetime. If she prefers fecal testing, she should understand the limitations of onetime testing for the detection of advanced polyps and cancer and the need for repeat testing over the next few years.
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